company background image

Anhui Anke Biotechnology (Group) SZSE:300009 Stock Report

Last Price


Market Cap







08 Aug, 2022


Company Financials +
300009 fundamental analysis
Snowflake Score
Future Growth6/6
Past Performance1/6
Financial Health6/6

300009 Stock Overview

Anhui Anke Biotechnology (Group) Co., Ltd.

Anhui Anke Biotechnology (Group) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Anhui Anke Biotechnology (Group)
Historical stock prices
Current Share PriceCN¥9.40
52 Week HighCN¥14.20
52 Week LowCN¥7.34
1 Month Change-6.75%
3 Month Change-0.32%
1 Year Change-28.95%
3 Year Change-2.50%
5 Year Change22.13%
Change since IPO202.43%

Recent News & Updates

Shareholder Returns

300009CN BiotechsCN Market

Return vs Industry: 300009 exceeded the CN Biotechs industry which returned -33.3% over the past year.

Return vs Market: 300009 underperformed the CN Market which returned -10.4% over the past year.

Price Volatility

Is 300009's price volatile compared to industry and market?
300009 volatility
300009 Average Weekly Movement4.1%
Biotechs Industry Average Movement5.6%
Market Average Movement6.1%
10% most volatile stocks in CN Market9.2%
10% least volatile stocks in CN Market3.9%

Stable Share Price: 300009 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 300009's weekly volatility (4%) has been stable over the past year.

About the Company

20002,384Lihua Song

Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers recombinant human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name.

Anhui Anke Biotechnology (Group) Fundamentals Summary

How do Anhui Anke Biotechnology (Group)'s earnings and revenue compare to its market cap?
300009 fundamental statistics
Market CapCN¥15.42b
Earnings (TTM)CN¥253.94m
Revenue (TTM)CN¥2.22b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
300009 income statement (TTM)
Cost of RevenueCN¥449.76m
Gross ProfitCN¥1.77b
Other ExpensesCN¥1.51b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)0.15
Gross Margin79.72%
Net Profit Margin11.45%
Debt/Equity Ratio0%

How did 300009 perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio
We’ve recently updated our valuation analysis.


Is 300009 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300009?

Other financial metrics that can be useful for relative valuation.

300009 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6.5x
Enterprise Value/EBITDA20x
PEG Ratio1.5x

Price to Earnings Ratio vs Peers

How does 300009's PE Ratio compare to its peers?

300009 PE Ratio vs Peers
The above table shows the PE ratio for 300009 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average35.7x
688739 Liaoning Chengda BiotechnologyLtd
002675 Yantai Dongcheng Pharmaceutical GroupLtd
301047 Sino BiologicalInc
688298 Zhejiang Orient Gene Biotech
300009 Anhui Anke Biotechnology (Group)

Price-To-Earnings vs Peers: 300009 is expensive based on its Price-To-Earnings Ratio (60.7x) compared to the peer average (35.7x).

Price to Earnings Ratio vs Industry

How does 300009's PE Ratio compare vs other companies in the CN Biotechs Industry?

Price-To-Earnings vs Industry: 300009 is expensive based on its Price-To-Earnings Ratio (60.7x) compared to the CN Biotechs industry average (35.4x)

Price to Earnings Ratio vs Fair Ratio

What is 300009's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300009 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio60.7x
Fair PE Ratio36.5x

Price-To-Earnings vs Fair Ratio: 300009 is expensive based on its Price-To-Earnings Ratio (60.7x) compared to the estimated Fair Price-To-Earnings Ratio (36.5x).

Share Price vs Fair Value

What is the Fair Price of 300009 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300009 (CN¥9.4) is trading below our estimate of fair value (CN¥33.4)

Significantly Below Fair Value: 300009 is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Anhui Anke Biotechnology (Group) forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score


Future Growth Score 6/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300009's forecast earnings growth (40.2% per year) is above the savings rate (3.2%).

Earnings vs Market: 300009's earnings (40.2% per year) are forecast to grow faster than the CN market (24.5% per year).

High Growth Earnings: 300009's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 300009's revenue (22.5% per year) is forecast to grow faster than the CN market (17.8% per year).

High Growth Revenue: 300009's revenue (22.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300009's Return on Equity is forecast to be high in 3 years time (21.8%)

Discover growth companies

Past Performance

How has Anhui Anke Biotechnology (Group) performed over the past 5 years?

Past Performance Score


Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 300009 has a large one-off loss of CN¥292.4M impacting its March 31 2022 financial results.

Growing Profit Margin: 300009's current net profit margins (11.5%) are lower than last year (21.5%).

Past Earnings Growth Analysis

Earnings Trend: 300009's earnings have grown by 5.6% per year over the past 5 years.

Accelerating Growth: 300009's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 300009 had negative earnings growth (-37%) over the past year, making it difficult to compare to the Biotechs industry average (9.7%).

Return on Equity

High ROE: 300009's Return on Equity (8.1%) is considered low.

Discover strong past performing companies

Financial Health

How is Anhui Anke Biotechnology (Group)'s financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 300009's short term assets (CN¥2.0B) exceed its short term liabilities (CN¥619.6M).

Long Term Liabilities: 300009's short term assets (CN¥2.0B) exceed its long term liabilities (CN¥149.7M).

Debt to Equity History and Analysis

Debt Level: 300009 is debt free.

Reducing Debt: 300009 has no debt compared to 5 years ago when its debt to equity ratio was 3.4%.

Debt Coverage: 300009 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 300009 has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies


What is Anhui Anke Biotechnology (Group) current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 5/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 300009's dividend (2.13%) is higher than the bottom 25% of dividend payers in the CN market (0.47%).

High Dividend: 300009's dividend (2.13%) is in the top 25% of dividend payers in the CN market (1.93%)

Stability and Growth of Payments

Stable Dividend: 300009's dividends per share have been stable in the past 10 years.

Growing Dividend: 300009's dividend payments have increased over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: With its high payout ratio (125.3%), 300009's dividend payments are not well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its reasonable cash payout ratio (69.5%), 300009's dividend payments are covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average board tenure


Lihua Song (47 yo)

no data




Mr. Song Lihua serves as the Chairman of the Board and President at Anhui Anke Biotechnology (Group) Co., Ltd and its Director since May 1, 1993.

Board Members

Experienced Board: 300009's board of directors are seasoned and experienced ( 10.6 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Anhui Anke Biotechnology (Group) Co., Ltd.'s employee growth, exchange listings and data sources

Key Information

  • Name: Anhui Anke Biotechnology (Group) Co., Ltd.
  • Ticker: 300009
  • Exchange: SZSE
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CN¥15.418b
  • Shares outstanding: 1.64b
  • Website:

Number of Employees


  • Anhui Anke Biotechnology (Group) Co., Ltd.
  • AnkeBio Building
  • 669 Changjiang Road, West
  • Hefei
  • Anhui Province
  • 230088
  • China


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/08 00:00
End of Day Share Price2022/08/08 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.